[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lewy-body-diseaselbd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lewy-body-diseaselbd":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100417416","upenn-observational-research-repository-on-neurodegenerative-disease-100417416",false,"NCT04715399","UPenn Observational Research Repository on Neurodegenerative Disease","University of Pennsylvania Centralized Observational Research Repository on Neurodegenerative Disease (UNICORN)","UNICORN","Inclusion Criteria:\n\nThis protocol will include 3 groups of people:\n\n1. People with a clinical diagnosis of a neurodegenerative disease. such as frontotemporal degeneration(FTD), primary progressive aphasia(PPA), Lewy body disease(LBD), amyotrophic lateral sclerosis(ALS), progressive supranuclear palsy(PSP), corticobasal syndrome(CBS), posterior cortical atrophy(PCA), Alzheimer's disease(AD), Parkinson's disease(PD)\n2. People with a family history of neurodegenerative disease who may or may not be symptomatic, and may or may not be mutation carriers such as familial frontotemporal lobar degeneration (fFTLD) or familial ALS,\n3. People with no known neurological disease who will provide control data.\n\nExclusion Criteria:\n\n* Anyone who is under the age of 18.\n* Anyone with a condition or in a situation which, in the Investigator's opinion, could confound the study findings or may interfere significantly with a person's participation, including but not limited to neurological, psychological and other medical conditions (such as cardiac, neurosurgical, infectious conditions).\n* Individual participants may be excluded from some, but not all, study procedures for safety reasons when they have a contraindication or at the discretion of the Investigator. For example, persons with metal implants which are not MRI-safe will not be able to take part in imaging, and those on blood thinning medications may not be able to take part in lumbar puncture.\n* Pregnant women; if a woman becomes pregnant during the study, research activities that may increase risk to the patient and the unborn fetus will be stopped until the end of pregnancy, at which point participation can be resumed.",true,"ALL","18 Years",{"count":21,"type":22},1000,"ESTIMATED","OBSERVATIONAL","The aim of this study is to create a repository of both cross-sectional and longitudinal data, including cognitive, linguistic, imaging and biofluid biological specimens, for neurodegenerative disease research and treatment.",[26,27,28,29,30,31,32,33,34],"Frontotemporal Degeneration(FTD)","Primary Progressive Aphasia(PPA)","Familial Frontotemporal Lobar Degeneration (fFTLD)","Amyotrophic Lateral Sclerosis(ALS)","Lewy Body Disease(LBD)","Progressive Supranuclear Palsy(PSP)","Corticobasal Syndrome(CBS)","Posterior Cortical Atrophy(PCA)","Alzheimer's Disease(AD)","RECRUITING","2026-01-21",{"date":38,"type":39},"2026-01-22","ACTUAL",{"date":41,"type":39},"2020-05-29",{"date":43,"type":22},"2070-05-30",{"name":45,"class":46},"University of Pennsylvania","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":17,"sex":18,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":60,"conditions":61,"keywords":71,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100316694","comprehensive-assessment-of-neurodegeneration-and-dementia-100316694","NCT03402919","Comprehensive Assessment of Neurodegeneration and Dementia","The Comprehensive Assessment of Neurodegeneration and Dementia Study","COMPASS-ND","Inclusion Criteria:\n\n* Has subjective or objective cognitive impairment\n* Written informed consent must be obtained and documented (from the patient or, where jurisdictions allow it, from a caregiver\u002Ffamily member)\n* Sufficient proficiency in English or French to undertake self report and neuropsychological testing\n* Geographic accessibility to the study site\n* Must have a study partner who can participate as required in the protocol (provide corroborative information)\n* Up to 12 years of education\n* Fits into one of the following groups: Cognitively Unimpaired, Subjective Cognitive Impairment, Mild Cognitive Impairment, Vascular Mild Cognitive Impairment, Parkinson's Disease, Parkinson's Disease with Mild Cognitive Impairment\n\nExclusion Criteria:\n\n* The presence of other significant known chronic brain disease such as: moderate to severe chronic static leukoencephalopathy (including previous traumatic injury), multiple sclerosis, a serious developmental handicap, malignant tumors, Parkinson's disease (other than for the Parkinson's cohort), and other rarer brain illnesses\n* Ongoing alcohol or drug abuse which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures\n* Symptomatic stroke within the previous year\n* Unable to undergo MRI scan due to medical contraindications or inability to tolerate the procedure","50 Years","90 Years",{"count":59,"type":22},1573,"This is a longitudinal observational study recruiting individuals between the ages of 50 and 90 with different types of dementia as well as a comparison group without cognitive deficits. Participants are\u002Fwill be recruited at sites across Canada and will undergo assessments, neuroimaging, and biological sample collection.",[62,63,64,65,30,66,67,68,69,70],"Dementia","Mild Cognitive Impairment (MCI)","Subjective Cognitive Impairment","Parkinson's Disease (PD)","Mixed Dementia","Frontotemporal Dementia (FTD)","Alzheimer Disease (AD)","Cognitively Unimpaired","Subjective Cognitive Decline (SCD)",[72,62,73,74,75,76,77,78,79,80],"Observational","Alzheimer's Disease","Parkinson's Disease","Biosample","Genetics","Neuropsychological","MRI","Microbiome","Plasma","2026-01-15",{"date":83,"type":39},"2026-01-20",{"date":85,"type":39},"2016-06",{"date":87,"type":22},"2029-12",{"name":89,"class":46},"McGill University",19]